Following FDA approval, the MoMe ARC is expected to make its market debut in the fourth quarter of 2023. Credit: JHVEPhoto/Shutterstock

The virtual telemetry company, InfoBionic, has received US Food and Drug Administration (FDA) 510(k) clearance MoMe ARC solution.

The MoMe ARC incorporates a remote Electrocardiography (ECG) monitoring device and an initial Bluetooth diagnostic 6-lead sensor, to aid clinicians in their diagnosis of cardiac arrhythmias in patients with a need for cardiac monitoring.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It transmits ECG data in near-real-time, analysed by the MoMe software platform’s server-based algorithms, ensuring timely and accurate identification of crucial data for clinician review.

InfoBionic also claims the device is designed so patients can wear it discretely and comfortably during monitoring using standard electrodes.

Dave MacCutcheon, the Chief Operating Officer, said: “We’re thrilled to announce FDA 510(k) clearance to market the MoMe ARC solution, which supports our mission to create superior patient monitoring solutions for arrhythmia detection and virtual care and chronic disease management.”

This device builds on its predecessor, the MoMe Kardia II, by introducing a decoupled 2-channel – 6-Lead Sensor, equipped with foundational technologies for compatibility with other Bluetooth-enabled health monitoring devices.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

MacCutcheon added: “MoMe ARC is a solution that includes a 4-in-1 Gateway device that seamlessly transitions between 2-day in addition to Extended Holter tests, Event and MCT modes remotely, streamlining patient monitoring time and minimizing delays. In addition, MoMe® ARC leverages a comprehensive cloud-based proprietary platform to deliver on-demand, actionable data and analytics directly to the clinicians.”

Following FDA approval, the MoMe ARC is expected to make its market debut in the fourth quarter of 2023.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact